Craft

Biodesix

Stock Price

$1.6

2024-10-29

Market Capitalization

$239.5 M

2024-10-29

Revenue

$88.5 M

FY, 2025

Biodesix Summary

Company Summary

Overview
Biodesix is a company that provides data-driven diagnostic solutions. Its tests include Nodify Lung, proteomic tests designed to help providers decipher the risk of malignancy of a lung nodule, and IQLung, treatment guidance testing for lung cancer.
Type
Public
Status
Active
Founded
2005
HQ
Boulder, CO, US | view all locations
Website
http://www.biodesix.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Scott Hutton

    Scott Hutton, Chief Executive Officer

  • Robin Harper-Cowie

    Robin Harper-Cowie, Chief Financial Officer

  • Gary Pestano

    Gary Pestano, Chief Development Officer

  • Steve Springmeyer

    Steve Springmeyer, Co-Chief Medical Officer

Operating MetricsView all

Blood-Based Tests Offered

4

Q2, 2020

Completed Clinical Studies to Date

23

Q2, 2020

Active Clinical Studies

4

Q2, 2020

LocationsView all

2 locations detected

  • Boulder, CO HQ

    United States

    2970 Wilderness Place, Suite 100

  • De Soto, KS

    United States

    8960 Commerce Dr, Building 6

Biodesix Financials

Summary Financials

Revenue (Q1, 2026)
$25.6M
Net income (Q1, 2026)
($7.8M)
Cash (Q1, 2026)
$25.6M
EBIT (Q1, 2026)
($6.2M)
Enterprise value
$285.6M

Footer menu